Total Payments
$2,108
2024 Payments
$80.00
Companies
4
Transactions
16
Payment Breakdown by Category
Research$1,456 (69.1%)
Travel$505.17 (24.0%)
Food & Beverage$146.88 (7.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,456 | 8 | 69.1% |
| Travel and Lodging | $505.17 | 1 | 24.0% |
| Food and Beverage | $146.88 | 7 | 7.0% |
Payments by Type
Research
$1,456
8 transactions
General
$652.05
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,456 | 8 | $0 (2020) |
| SANOFI PASTEUR INC. | $522.66 | 2 | $0 (2023) |
| GlaxoSmithKline, LLC. | $106.02 | 5 | $0 (2024) |
| Hologic Sales and Service, LLC | $23.37 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $80.00 | 4 | GlaxoSmithKline, LLC. ($56.63) |
| 2023 | $66.88 | 3 | GlaxoSmithKline, LLC. ($49.39) |
| 2020 | $1,456 | 8 | Takeda Pharmaceuticals U.S.A., Inc. ($1,456) |
| 2019 | $505.17 | 1 | SANOFI PASTEUR INC. ($505.17) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: RESPIRATORY | ||||||
| 05/07/2024 | Hologic Sales and Service, LLC | APTIMA (Device), THINPREP 2000 PROCESSOR | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Diagnostics | ||||||
| 03/05/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: VACCINES | ||||||
| 01/29/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: RESPIRATORY | ||||||
| 11/09/2023 | SANOFI PASTEUR INC. | VAXELIS (Biological), BEYFORTUS, MENQUADFI | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Vaccines | ||||||
| 10/18/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: VACCINES | ||||||
| 08/09/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $25.81 | General |
| Category: VACCINES | ||||||
| 01/30/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $59.54 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/30/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $43.30 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/30/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $25.27 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/30/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $24.35 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/29/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $187.19 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/29/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $132.00 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/29/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $89.73 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 01/28/2020 | Takeda Pharmaceuticals U.S.A., Inc. | INTUNIV (Drug) | — | Cash or cash equivalent | $894.79 | Research |
| Study: A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER • Category: NEUROSCIENCE | ||||||
| 05/23/2019 | SANOFI PASTEUR INC. | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $505.17 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | Takeda Pharmaceuticals U.S.A., Inc. | $1,456 | 8 |
About Dr. Maria Delgado, MD
Dr. Maria Delgado, MD is a Pediatrics healthcare provider based in Homestead, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1689672867.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maria Delgado, MD has received a total of $2,108 in payments from pharmaceutical and medical device companies, with $80.00 received in 2024. These payments were reported across 16 transactions from 4 companies. The most common payment nature is "" ($1,456).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties General Practice, Family Medicine
- Location Homestead, FL
- Active Since 07/12/2005
- Last Updated 08/17/2021
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1689672867
Products in Payments
- INTUNIV (Drug) $1,456
- NO PRODUCT DISCUSSED (Drug) $505.17
- SHINGRIX (Biological) $63.99
- AREXVY (Drug) $42.03
- APTIMA (Device) $23.37
- VAXELIS (Biological) $17.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Homestead
Dr. Dorsey Goosby, M.d, M.D
Pediatrics — Payments: $1,755
Pediatrics $1,755
Dr. Mario Zambrano, Md, MD
Pediatrics — Payments: $1,250
Pediatrics $1,250
Rosa Junco-Diaz, Md, MD
Pediatrics — Payments: $1,025
Pediatrics $1,025
Wanda Rodriguez, Md, MD
Pediatrics — Payments: $897.49
Pediatrics $897.49
Nicole Fields, Do, DO
Pediatrics — Payments: $775.94
Pediatrics $775.94
Dr. Martha Katz, M.d, M.D
Pediatrics — Payments: $607.61
Pediatrics $607.61